Estrella Immunopharma, Inc.
ESLA
Analytical Summary
Estrella Immunopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Jun 30, 2024 10-K ↗ | FY 2024 Jun 30, 2023 10-K ↗ | FY 2023 Dec 31, 2021 10-K ↗ | FY 2022 Jan 31, 2021 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
99.3%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — |
| Net Income Growth YoY (%) |
34.2%
Excellent
Excellent
Year-over-year change in net income |
-4386.7%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
86.4%
Excellent
Excellent
Year-over-year change in free cash flow |
-1530.1%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Jun 30, 2024 10-K ↗ | FY 2024 Jun 30, 2023 10-K ↗ | FY 2023 Dec 31, 2021 10-K ↗ | FY 2022 Jan 31, 2021 10-K ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
-0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| FCF / Net Income (x) |
2.20x
Excellent
↑
Excellent
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.12x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.28x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Jun 30, 2024 10-K ↗ | FY 2024 Jun 30, 2023 10-K ↗ | FY 2023 Dec 31, 2021 10-K ↗ | FY 2022 Jan 31, 2021 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-171.1%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
74.8%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
24.8%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-164.1%
Weak
↑
Weak
Improving
Operating profit relative to total assets
Optimal:
> 10%
|
-367.0%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-0.5%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-171.1%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1241%)
|
94.7%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+531%)
|
24.6%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+64%)
|
— |
Secondary lens
Benchmark Lens
Compare ESLA against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare ESLA against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for ESLA
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How ESLA compares to all companies
Peer Comparison
ESLA vs similar peers
Compare ESLA with peers
Stack ESLA against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 15 quarters